Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 83.56
(1.27%)
INR 83.56
(1.27%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.86 Billion INR | -1.46% |
| 2022 | 2.35 Billion INR | 3.74% |
| 2021 | 2.23 Billion INR | 25.19% |
| 2020 | 1.98 Billion INR | 15.04% |
| 2019 | 1.77 Billion INR | 11.57% |
| 2018 | 1.48 Billion INR | 2.19% |
| 2017 | 1.48 Billion INR | 34.01% |
| 2016 | 1.22 Billion INR | 3.46% |
| 2015 | 1.18 Billion INR | 17.32% |
| 2014 | 582.26 Million INR | 112.16% |
| 2013 | 110.23 Million INR | 95.27% |
| 2012 | 82.46 Million INR | -87.25% |
| 2011 | 1.75 Billion INR | -5.11% |
| 2010 | 1.85 Billion INR | 25.21% |
| 2009 | 1.43 Billion INR | 15.17% |
| 2008 | 1.26 Billion INR | 38.26% |
| 2007 | 884.5 Million INR | 48.57% |
| 2006 | 627.26 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -97.4 Million INR | -99.64% |
| 2023 Q1 | 659.05 Million INR | -4.72% |
| 2023 FY | - INR | -1.46% |
| 2023 Q4 | -373 Million INR | -163.43% |
| 2023 Q3 | 588.04 Million INR | -19.55% |
| 2023 Q2 | 730.92 Million INR | 10.9% |
| 2022 Q1 | 603.95 Million INR | -10.52% |
| 2022 FY | - INR | 3.74% |
| 2022 Q4 | 691.69 Million INR | 11.35% |
| 2022 Q3 | 621.21 Million INR | -6.3% |
| 2022 Q2 | 662.99 Million INR | 9.78% |
| 2021 Q1 | 571.98 Million INR | 54.97% |
| 2021 Q4 | 674.92 Million INR | 11.01% |
| 2021 Q3 | 607.99 Million INR | -3.8% |
| 2021 Q2 | 632.02 Million INR | 10.5% |
| 2021 FY | - INR | 25.19% |
| 2020 FY | - INR | 15.04% |
| 2020 Q2 | 547.23 Million INR | 11.0% |
| 2020 Q3 | 572.84 Million INR | 4.68% |
| 2020 Q4 | 369.08 Million INR | -35.57% |
| 2020 Q1 | 492.99 Million INR | -20.52% |
| 2019 Q4 | 620.25 Million INR | 32.37% |
| 2019 FY | - INR | 11.57% |
| 2019 Q3 | 468.55 Million INR | 18.05% |
| 2019 Q2 | 396.91 Million INR | -12.7% |
| 2019 Q1 | 454.67 Million INR | 14.28% |
| 2018 Q2 | 445.51 Million INR | 29.77% |
| 2018 FY | - INR | 2.19% |
| 2018 Q4 | 397.84 Million INR | -7.35% |
| 2018 Q1 | 343.3 Million INR | 0.0% |
| 2018 Q3 | 429.42 Million INR | -3.61% |
| 2017 FY | - INR | 34.01% |
| 2016 FY | - INR | 3.46% |
| 2015 FY | - INR | 17.32% |
| 2014 FY | - INR | 112.16% |
| 2013 FY | - INR | 95.27% |
| 2012 Q2 | 301.26 Million INR | 414.62% |
| 2012 FY | - INR | -87.25% |
| 2012 Q3 | 312.46 Million INR | 3.72% |
| 2012 Q1 | -95.75 Million INR | 0.0% |
| 2012 Q4 | -293.21 Million INR | -193.84% |
| 2011 FY | - INR | -5.11% |
| 2010 FY | - INR | 25.21% |
| 2009 FY | - INR | 15.17% |
| 2008 FY | - INR | 38.26% |
| 2007 FY | - INR | 48.57% |
| 2006 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 95.041% |
| NATCO Pharma Limited | 18.79 Billion INR | 63.492% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -46.704% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -1494.706% |
| Achyut Healthcare Limited | 524 Thousand INR | -1309372.519% |
| Ajanta Pharma Limited | 12.56 Billion INR | 45.393% |
| Alkem Laboratories Limited | 24.19 Billion INR | 71.64% |
| Alpa Laboratories Limited | 86.12 Million INR | -7866.881% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 28.649% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -191.142% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 88.895% |
| Bajaj HealthCare Limited | 444.51 Million INR | -1443.62% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -363.928% |
| Brooks Laboratories Limited | 41.72 Million INR | -16343.721% |
| Divi's Laboratories Limited | 25.43 Billion INR | 73.018% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 92.227% |
| Eris Lifesciences Limited | 6.98 Billion INR | 1.787% |
| FDC Limited | 4.4 Billion INR | -55.886% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 39.511% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 0.018% |
| Granules India Limited | 8.6 Billion INR | 20.249% |
| Gufic Biosciences Limited | 1.48 Billion INR | -363.472% |
| Hester Biosciences Limited | 539.47 Million INR | -1171.922% |
| Indoco Remedies Limited | 2.64 Billion INR | -159.218% |
| Ipca Laboratories Limited | 13.29 Billion INR | 48.407% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -2021.324% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 8394.313% |
| Lasa Supergenerics Limited | -65.08 Million INR | 10643.387% |
| Laurus Labs Limited | 8 Billion INR | 14.294% |
| Lupin Limited | 36.96 Billion INR | 81.44% |
| Mankind Pharma Limited | 28.09 Billion INR | 75.577% |
| Medicamen Biotech Limited | 245.66 Million INR | -2693.143% |
| Medico Remedies Limited | 150.37 Million INR | -4462.925% |
| Megasoft Limited | 284.73 Million INR | -2309.866% |
| Piramal Pharma Limited | 13.05 Billion INR | 47.442% |
| RPG Life Sciences Limited | 1.28 Billion INR | -435.438% |
| Sigachi Industries Limited | 883.39 Million INR | -676.732% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 283.896% |
| Unichem Laboratories Limited | 742.35 Million INR | -824.305% |
| Wanbury Limited | 985.49 Million INR | -596.266% |
| Windlas Biotech Limited | 781.72 Million INR | -777.761% |
| ZIM Laboratories Limited | 462.09 Million INR | -1384.891% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 87.795% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -127.629% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -905.312% |
| Bal Pharma Limited | 345.59 Million INR | -1885.473% |
| Strides Pharma Science Limited | 3.76 Billion INR | -82.263% |
| Venus Remedies Limited | 711.8 Million INR | -863.982% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -75.515% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -338.782% |
| Shilpa Medicare Limited | 2.58 Billion INR | -165.135% |
| Aarti Drugs Limited | 3.24 Billion INR | -111.216% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -163.241% |
| Suven Life Sciences Limited | -992.78 Million INR | 791.154% |
| Ind-Swift Limited | 1.06 Billion INR | -544.245% |
| Valiant Laboratories Limited | 12.73 Million INR | -53763.223% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 26.494% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 343.157% |
| Themis Medicare Limited | 562.6 Million INR | -1119.614% |
| Hikal Limited | 2.69 Billion INR | -154.868% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 80.401% |
| Sequent Scientific Limited | 549.8 Million INR | -1148.024% |
| Novartis India Limited | 1.26 Billion INR | -440.584% |
| Wockhardt Limited | 1.08 Billion INR | -535.337% |
| Jubilant Pharmova Limited | 8 Billion INR | 14.294% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -52431.282% |
| Neuland Laboratories Limited | 4.74 Billion INR | -44.511% |
| Morepen Laboratories Limited | 1.72 Billion INR | -297.556% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -2287.279% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -3822.145% |